RecruitingPhase 2Phase 3NCT07339345

Prospective Single-Arm Clinical Trial of GO Regimen for HLH.

Prospective Single-Arm Clinical Trial of Golidocitinib Monotherapy for Hemophagocytic Lymphohistiocytosis.

Sponsor

Beijing Friendship Hospital

Enrollment

28 participants

Start Date

Jun 27, 2025

Study Type

INTERVENTIONAL

Conditions

Lymphohistiocytosis, Hemophagocytic

Summary

This study aims to investigate the efficacy and safety of Golidocitinib(GO) monotherapy in the treatment of hemophagocytic lymphohistiocytosis.

Eligibility

Min Age: 14 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Golidocitinib for people with lymphohistiocytosis, hemophagocytic. The study is currently recruiting participants at 1 location. People eligible for this study include aged 14 Years to 70 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGGolidocitinib

Administer the GO regimen to HLH patients who meet the inclusion criteria, specifically Golicitinib 150 mg once daily.

Locations(1)

beijing Friendship Hospital, Capital Medical University

Beijing, Beijing Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07339345

Related Trials

Hemophagocytic Lymphohistiocytosis (HLH) Evaluation and Research of Clinical, ImmUnoLogic and TranscriptomE Study

NCT063391772 locations